跳转至内容
Merck

Y0000500

阿卡波糖

European Pharmacopoeia (EP) Reference Standard

别名:

阿卡波糖, 4",6"-二脱氧-4"-([1S]-[1,4,6/5]-4,5,6-三羟基-3-羟甲基-2-环己烯基氨基)-麦芽三糖

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H43NO18
CAS号:
分子量:
645.60
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

agency

EP Reference Standard

API 家族

acarbose

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1

InChI 密鑰

XUFXOAAUWZOOIT-SXARVLRPSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

應用

阿卡波糖EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

作为可逆性α-葡萄糖苷酶抑制剂的改性四糖。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jun-Peng Yang et al.
Journal of agricultural and food chemistry, 62(31), 7760-7770 (2014-07-16)
Bamboo leaf extract as a food additive has been used for preventing the oxidation of food. In the present study, we investigated the influence of Phyllostachys edulis leaf extract on starch digestion. Orientin, isoorientin, vitexin, and isovitexin were determined as
Uwe Zeymer
International journal of cardiology, 107(1), 11-20 (2005-12-13)
Impaired glucose metabolism is associated with an increased risk of cardiovascular events and cardiovascular-associated mortality. Postprandial hyperglycaemia is one of the earliest identifiable indicators of impaired glucose control. It contributes to the progression from impaired glucose tolerance to overt type
Sho-ichi Yamagishi et al.
Current drug metabolism, 10(2), 159-163 (2009-03-12)
Diabetes is associated with an increase risk for cardiovascular disease (CVD). Recently, macrovascular complications of diabetes have been shown to start before the development of diabetes. Indeed, several clinical studies have confirmed the increased risk of CVD in patients with
Rury R Holman et al.
American heart journal, 168(1), 23-29 (2014-06-24)
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce
H W M Breuer
International journal of clinical pharmacology and therapeutics, 41(10), 421-440 (2004-01-06)
Acarbose--the most extensively investigated and widely prescribed alpha-glucosidase inhibitor--reduces postprandial plasma glucose excursions by delaying the absorption of carbohydrate from the small intestine. Acarbose is an effective first-line therapy for patients with newly diagnosed type 2 diabetes, and induces a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门